Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023

Rhea-AI Summary

Immunocore (Nasdaq: IMCR) will report its 2022 earnings on March 1, 2023, before the US markets open. The company, known for its pioneering T cell receptor (TCR) bispecific immunotherapies, will host a live teleconference at 8:00 a.m. ET to discuss the financial results and provide updates. KIMMTRAK, Immunocore's leading oncology TCR therapy, is currently approved for treating HLA-A*02:01-positive adult patients with advanced uveal melanoma in several regions, including the US and Europe. Shareholders and interested parties can access the earnings call via the company’s website, with a replay available for 90 days.

Positive

• Immunocore to report 2022 earnings, indicating ongoing financial activities.
• KIMMTRAK approved in multiple regions, showcasing successful product development.

Negative

• None.

Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 February, 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announced  that it will report full year 2022 results, before the US markets open on Wednesday, March 1, 2023. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. ET (1:00 p.m. GMT) to discuss their financial results and provide a business and portfolio update.

Audio Webcast
The call will be made available via webcast by visiting the Events & Presentations section on Immunocore’s website. A replay of this webcast will be available for 90 days.

Conference Call Details:
Domestic (toll-free): 877-405-1239
International (toll): +1 201-389-0851

##

About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

CONTACT: 

Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore

Consilium Strategic Communications (corporate and financial)
Mary-Jane Elliott/ Chris Welsh/Jessica Hodgson
T: +44 (0)203 709 5700
E: Immunocore@consilium-comms.com

Investor Relations  
Clayton Robertson, Head of Investor Relations
T: +1 215-384-4781
E: ir@immunocore.com

FAQ

When will Immunocore report its Q4 and full year 2022 earnings?

Immunocore will report its Q4 and full year 2022 earnings on March 1, 2023.

What is the ticker symbol for Immunocore?

The ticker symbol for Immunocore is IMCR.

How can I access Immunocore's earnings call?

You can access Immunocore's earnings call via their website in the Events & Presentations section.

What is KIMMTRAK and what approval has it received?

KIMMTRAK is Immunocore's TCR therapy, approved for treating advanced uveal melanoma in several regions, including the US and Europe.